Robbins Geller Rudman & Dowd LLP, a prominent law firm specializing in securities litigation, has initiated a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). The lawsuit represents investors who purchased or acquired Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025. The legal action, filed in the District of New Jersey under the case number Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049, alleges that the company violated the Securities Exchange Act of 1934.

According to the complaint, Rocket Pharmaceuticals and a top executive are accused of making misleading statements and omitting critical information regarding the safety of its lead gene therapy program, RP-A501, which targets Danon disease. The lawsuit highlights several alleged failures by the company, including the introduction of a new immunomodulatory agent into the trial protocol without proper disclosure to shareholders, concealing serious adverse events (SAEs) such as a patient death, and amending the clinical trial protocol without informing investors, misleading them about the trial's progress and safety.

The situation escalated when, on May 27, 2025, Rocket Pharmaceuticals disclosed that the FDA had imposed a clinical hold on the RP-A501 trial following a patient's death. This revelation caused a significant drop in the company's stock price, prompting the current legal action to recover damages for the affected investors.

Investors have until August 11, 2025, to seek appointment as the lead plaintiff in the case. This role is typically filled by an investor who has suffered the most substantial financial loss and meets specific legal criteria. The lead plaintiff can direct the class action lawsuit and choose the legal counsel.

Rocket Pharmaceuticals, based in New Jersey, is known for its development of gene therapies for rare, life-threatening diseases using advanced technology platforms. Despite the current challenges, the company continues its efforts in various therapeutic areas.

Robbins Geller Rudman & Dowd LLP has established itself as a leader in handling complex legal matters, often representing institutional investors, individuals, and consumer groups across the United States. Their track record includes significant victories in landmark cases, highlighting their dedication to securing justice for clients.

Investors who purchased Rocket Pharmaceuticals securities during the Class Period and wish to learn more about the class action lawsuit can contact J.C. Sanchez or Jennifer N. Caringal at 800-449-4900 or via email at [email protected]. Additional details about the case are available on the Robbins Geller website.

For more insights and updates on related legal matters, interested parties can visit Lawyer Monthly or access specific case information through provided links.